Literature DB >> 7651649

Latency period after preterm premature rupture of membranes: a comparison of ampicillin with and without sulbactam.

D F Lewis1, M T Fontenot, G G Brooks, R Wise, M B Perkins, A R Heymann.   

Abstract

OBJECTIVE: To compare ampicillin with and without sulbactam with respect to the effect on the latency period after preterm premature rupture of membranes (PROM).
METHODS: Patients with PROM at 25-35 weeks' gestation were offered participation in a randomized blinded trial comparing ampicillin-sulbactam with ampicillin. Evaluations for cervical pathogens were performed on admission and patients were followed-up with daily maternal and fetal evaluation. Maternal and neonatal outcomes were analyzed using indicated techniques.
RESULTS: Fifty-three women were studied, with 25 receiving ampicillin-sulbactam and 28 receiving ampicillin. The ampicillin-sulbactam group had a significantly longer latency period (433 +/- 625 versus 143 +/- 165 hours, P = .03) and significantly fewer neonatal complications (five versus 20, P < .001). Although no neonatal infectious complications were observed in sulbactam-treated cases, there were four cases of neonatal sepsis and two of neonatal pneumonia in the ampicillin group. Also, significantly more neonates in the ampicillin group required prolonged oxygen and ventilatory support. There was no significant difference in maternal morbidity.
CONCLUSIONS: In our population with preterm PROM, a broad-spectrum antibiotic that provides anaerobic coverage appears to extend latency and decrease neonatal morbidity without increasing adverse maternal outcome.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7651649     DOI: 10.1016/0029-7844(95)00181-P

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  6 in total

1.  Prevalence and diversity of microbes in the amniotic fluid, the fetal inflammatory response, and pregnancy outcome in women with preterm pre-labor rupture of membranes.

Authors:  Daniel B DiGiulio; Roberto Romero; Juan Pedro Kusanovic; Ricardo Gómez; Chong Jai Kim; Kimberley S Seok; Francesca Gotsch; Shali Mazaki-Tovi; Edi Vaisbuch; Katherine Sanders; Elisabeth M Bik; Tinnakorn Chaiworapongsa; Enrique Oyarzún; David A Relman
Journal:  Am J Reprod Immunol       Date:  2010-03-21       Impact factor: 3.886

2.  Sterile and microbial-associated intra-amniotic inflammation in preterm prelabor rupture of membranes.

Authors:  Roberto Romero; Jezid Miranda; Piya Chaemsaithong; Tinnakorn Chaiworapongsa; Juan P Kusanovic; Zhong Dong; Ahmed I Ahmed; Majid Shaman; Kia Lannaman; Bo Hyun Yoon; Sonia S Hassan; Chong Jai Kim; Steven Jai Korzeniewski; Lami Yeo; Yeon Mee Kim
Journal:  J Matern Fetal Neonatal Med       Date:  2014-09-29

3.  Incidence of postpartum endomyometritis following single-dose antibiotic prophylaxis with either ampicillin/sulbactam, cefazolin, or cefotetan in high-risk cesarean section patients.

Authors:  N Noyes; A S Berkeley; K Freedman; W Ledger
Journal:  Infect Dis Obstet Gynecol       Date:  1998

4.  Developing a Core Outcome Set for the Evaluation of Antibiotic Use in Prelabor Rupture of Membranes: A Systematic Review and Semi-Structured Interview.

Authors:  Dan Liu; Lin Wu; Jiefeng Luo; Siyu Li; Yan Liu; Chuan Zhang; Linan Zeng; Qin Yu; Lingli Zhang
Journal:  Front Pharmacol       Date:  2022-08-01       Impact factor: 5.988

Review 5.  The Management of Pregnancy Complicated with the Previable Preterm and Preterm Premature Rupture of the Membranes: What about a Limit of Neonatal Viability?-A Review.

Authors:  Stepan Feduniw; Zuzanna Gaca; Olga Malinowska; Weronika Brunets; Magdalena Zgliczyńska; Marta Włodarczyk; Anna Wójcikiewicz; Michał Ciebiera
Journal:  Diagnostics (Basel)       Date:  2022-08-22

6.  A new rapid bedside test to diagnose and monitor intraamniotic inflammation in preterm PROM using transcervically collected fluid.

Authors:  Kyung Joon Oh; JoonHo Lee; Roberto Romero; Hyun Soo Park; Joon-Seok Hong; Bo Hyun Yoon
Journal:  Am J Obstet Gynecol       Date:  2020-02-27       Impact factor: 10.693

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.